Skip to main content
Internal view of patient's torso demonstrating targeted accuracy of TheraSphere Y-90 Glass Microspheres in liver.

TheraSphere™ Y-90 Glass Microspheres

Clinical data details

Hepatocellular Carcinoma (HCC)

Explore clinical data at different HCC stages

LEGACY study 

Learn how the LEGACY study confirms TheraSphere as a neoadjuvant or standalone therapy in treating HCC.

View the LEGACY study

1000-Patient study

Institutional decision to adopt Y-90 as a primary treatment for HCC informed by a 1000-patient 15-year study.

View the 1000-patient study 

Data in Bridging and Downstaging to Surgery

15-year, 207 patient study demonstrating data on TheraSphere in patients with HCC needing to be bridged or downstaged to Liver Transplant therapy with a median overall survival of 12.5 years. 

View the data

Radiation Segmentectomy 

A retrospective study to report one center’s long-term outcomes of patients with HCC ≤ 5 cm, not amenable to transplantation, resection or RF ablation, who underwent radiation segmentectomy.

View the Radiation Segmentectomy findings

RASER study

First prospective study to assess outcomes after radiation segmentectomy in patients with very early or early stage HCC which showed 100% initial objective response with TheraSphere.

View the RASER study

ROWAN study

ROWAN will assess the durability of local tumor control in HCC patients who receive TheraSphere followed by Durvalumab and Tremelimumab, compared to those who receive TheraSphere treatment alone.

View the ROWAN study

TARGET study

A global real-world retrospective study demonstrating TheraSphere for HCC with predictable clinical outcomes across a broad patient population in eight countries.

View the TARGET study

1000-Patient study*

Institutional decision to adopt Y-90 as a primary treatment for HCC informed by a 1000-patient 15-year study.

View the 1000-patient study 

Data in Bridging and Downstaging to Surgery*

15-year, 207 patient study demonstrating data on TheraSphere in patients with HCC needing to be bridged or downstaged to Liver Transplant therapy with a median overall survival of 12.5 years. 

View the data

DOSISPHERE-01 trial*

A randomized, multicenter, investigator-sponsored phase II trial comparing the clinical outcomes of SIRT with TheraSphere in patients with intermediate/advanced HCC, with single vs. multi-compartment dosimetry.

View the DOSISPHERE-01 trial

LEGACY study *

Learn how the LEGACY study confirms TheraSphere as a neoadjuvant or standalone therapy in treating HCC.

View the LEGACY study 

PROACTIF study*

A prospective, real-world, Y-90 study with TheraSphere for the treatment of liver malignancies: interim analysis of 873 hepatocellular carcinoma (HCC) patients.

View the PROACTIF study HCC data

ROWAN study*

ROWAN will assess the durability of local tumor control in HCC patients who receive TheraSphere followed by Durvalumab and Tremelimumab, compared to those who receive TheraSphere treatment alone.

View the ROWAN study

TARGET study*

A global real-world retrospective study demonstrating TheraSphere for HCC with predictable clinical outcomes across a broad patient population in eight countries.

View the TARGET study

Metastatic Colorectal Cancer (mCRC)*

Explore clinical data for mCRC

EPOCH trial

A phase III clinical trial evaluating TheraSphere as a second-line therapy in patients with metastatic colorectal carcinoma of the liver who have failed first-line chemotherapy. 

View the EPOCH trial

Caution: In the US, TheraSphere is under an investigational device exemption to treat patients with metastatic colorectal cancer. The safety and effectiveness of this treatment have not been established.

Y-90 vs. other LRTs

Explore clinical data for Y-90 vs. other locoregional therapy (LRT) options

PREMIERE and TRACE trials

Comparison of TARE treatment using TheraSphere to DEB-TACE** and cTACE in patients with HCC shows longer time to tumor progression as a cost-effective, efficient treatment option.

View the PREMIERE and TRACE trials

References

*TheraSphere is indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child- Pugh Score A cirrhosis, well compensated liver function, no macrovascular invasion, and good performance status.

**The loading of doxuribicin to LC Beads is outside of the indication for use in the USA.

TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.